MREO
Mereo BioPharma Group PLC ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$42.84M
P/E Ratio
—
EPS
$-0.25
Beta
0.38
52W High
$3.05
52W Low
$0.20
50-Day MA
$0.35
200-Day MA
$1.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 500,000 |
| Gross Profit (TTM) | 367,000 |
| EBITDA | $-37.94M |
| Operating Margin | -7711.00% |
| Return on Equity | -82.20% |
| Return on Assets | -39.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.26 |
| Price-to-Book | 1.08 |
| Price-to-Sales (TTM) | 85.68 |
| EV/Revenue | 6.66 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $159.62M |
| Float | $572.33M |
| % Insiders | 0.96% |
| % Institutions | 43.35% |
Historical Volatility
HV 10-Day
41.74%
HV 20-Day
44.93%
HV 30-Day
47.34%
HV 60-Day
66.00%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($1.78 target)
1
Strong Buy4
Buy3
HoldData last updated: 5/1/2026